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Abstract
Echinocandins represent the newest class of antifun-
gal agents. currently, three echinocandins, anidulafun-
gin, caspofungin and micafungin are licensed for clini-
cal use in various indications. they act as inhibitors of
b-(1,3)-glucan  synthesis  in  the  fungal  cell  wall  and
have a favorable pharmacological profile. they have a
broad spectrum of activity against all candida species.
Higher MIcﾴs have been observed against C. parap-
silosis and C.  guilliermondii. data from clinical trials
for invasive Candida infections / candidaemia suggest
that the clinical outcome of patients treated with ei-
ther drug may be very similar. a comparison has been
done  between  caspofungin  and  micafungin  but  for
anidulafungin a comparative trial with another echino  -
candin is still lacking. all three drugs are highly effec-
tive if not superior to treatment with either flucona-
zole  or  amphotericin  b,  particularly  in  well-defined
clinical  settings  such  as  invasive  Candida infections,
Candida oesophagitis  and  candidaemia.  differences
between  the  three  echinocandins  with  regard  to  the
route of metabolism, requirement for a loading dose,
dose adjustment in patients with moderate to severe
hepatic disease and different dosing schedules for dif-
ferent types of Candida infections have to be consid-
ered. Relevant drug-drug interactions of caspofungin
and  Micafungin  are  minimal.  anidulafungin  has  no
significant drug interactions at all. However, echino  -
candins  are  available  only  for  intravenous  use.  all
three agents have an excellent safety profile. 
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IntRoductIon
despite the rapid development of the triazoles in the
1990s and the availability of liposomal amphotericin
which replaced conventional amphotericin b and pro-
vided alternative options for treating invasive fungal
infections, complications due to fungal infections re-
main a serious clinical problem, especially in immuno-
compromised  patients.  this  population  includes
trans  plant  recipients  (solid  organ  and  stem  cells), 
patients  with  cancer,  patients  treated  in  internal 
and  surgical  Icuﾴs  or  other  treated  for  diseases 
with  immunosuppressive  agents  and  patients  with
HIv/aIds. Many factors have contributed to the rise
of several fungal infections in the last decades, includ-
ing  novel  and  more  aggressive  immunosuppressive
drugs and regimens, a high frequency of  instrumen-
tation and catheterization, frequent application of in-
travenous  catheters,  long-term  parenteral  nutrition
and  prolonged  use  of  broad-spectrum  antibiotics. 
En  hanced  survival  in  intensive  care  units  due  to 
advances in medicine also increases the patient popu-
lation  susceptible  to  secondary  fungal  infections 
[1; 2].
Candida infections have contributed significantly to
the mortality in immunosuppressed patients and treat-
ment  outcomes  for  invasive  candidosis  are  still  less
than optimal. candidaemia has been observed to be
the fourth leading cause of bloodstream infections in
pediatric patients, cancer patients, and hospitalized pa-
tients with mortality rates from 20% in pediatric pa-
tients to 47% in intensive care unit patients [3-5]. Can-
dida albicans is still the most commonly found isolate.
However, there has been a shift towards more azole-
resistant species (e.g. Candida glabrata) found in some
institutions,  paralleled  by  a  reduced  susceptibility  to
azole antifungals such as fluconazole which is com-
monly used for superficial and invasive Candida infec-
tions [6; 7]. the expert Panel of the Idsa favours an
echinocandin for first-line treatment of candidaemia
in non-granulocytopenic patients with moderately se-
vere to severe illness, as first-line treatment for granu-
locytopenic  patients,  patients  recently  exposed  to
azole,  candidaemia  caused  by  C.  glabrata,  and  /  or
suspected invasive candidosis caused by C. glabrata or
C. krusei [8].
Echinocandins are cyclic lipopeptide molecules that
inhibit the synthetic cell-wall enzyme complex b-1,3-
d-glucan synthase. Inability of the organism to build
b-1,3-d-glucan destabilizes the integrity of the fungal
cell wall, leading  to osmotic instability and cell death
[9; 10]. Echinocandins are fungicidal against yeast and
fungistatic against molds and have a similar spectrum
of antifungal activity. In addition, echinocandin activi-
ty  can  persist  in  a  drug  free  environment  following
drug exposure (post-antifungal effect) [11].
there are three echinocandins approved by the Eu-
ropean Medicines agency (EMEa) for the use in Eu-
rope, 1) caspofungin (MK-0991, cancidasﾮ; Merck &
co., Inc., whitehouse station, nJ, usa) derived from
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lafungin  (vER-002,  ly303366,  Eraxisﾮ,  Pfizer,  Inc.,
new york, ny, usa) derived from Aspergillus nidu-
lans and approved in 2007; and 3) Micafungin (fK-
463, Mycamineﾮ, astellas Pharma us, Inc., deerfield,
Il, usa) derived from Coleophoma  empedri was ap-
proved  in  2008  [12-14].  licensed  indications  in  Eu-
rope differ between the three agents. anidulafungin is
indicated to treat invasive candidosis in adults who are
not  granulocytopenic  but  not  in  children  or  adoles-
cents below the age of 18 years. caspofungin is indi-
cated to treat adults, adolescents and children with in-
vasive candidosis, invasive aspergillosis when the pa-
tient does not respond to or does not tolerate ampho-
tericin b or itraconazole; suspected fungal infections
(such as due to Candida or Aspergillus) when the pa-
tient is febrile and granulocytopenic. Micafungin is in-
dicated for adults, adolescents and children (including
neonates)    in  the  treatment  of  invasive  candidosis,
and prophylaxis of candida infection in patients un-
dergoing  allogeneic  haematopoietic  stem  cell  trans-
plantation or patients who are expected to have granu-
locytopenia (absolute neutrophil count < 500 cells /
ﾵl) for 10 or more days. In addition, micafungin is li-
censed  for  treatment  of  oesophageal  candidosis  in
adults  for  whom  intravenous  therapy  is  appropriate
[12-14].
as the incidence of fungal infections caused by flu-
conazole-resistant non-Candida-albicans species is in-
creasing,  echinocandins  have  become  an  important
group in the treatment of these types of infections be-
cause of lack of cross-resistance to azoles [15]. their
limited toxicity and a favorable drug-drug interactions
profile make them a viable alternative to conventional
treatment. 
cHEMIstRy
the echinocandins have significant structural differen  -
ces (s. fig. 1). Echinocandins are large lipopeptide mol-
ecules  synthetically  modified  from  the  fermentations
broths  of  various  fungi.  they  are  amphiphilic  cyclic
hexa  peptides with n-linked acyl lipid side-chain and a
molecular weight of about1200.themolecularformula
of caspofungin-acetate is c52H88n10 o15∙2c2H4o2
and it has a fatty acid side chain. Micafungin sodium
has a complex aromatic side-chain (3,5-diphenyl-sub-
stituted  isoxazole)  and  its  molecular  formula  is
c56H70n9nao23s.  anidulafungin’s  molecular  formula
is  c58H73n7o17 and  it  has  an  alkoxytriphenyl  side
chain. the side chains intercalate with the phospho-
lipid bilayer of the cell membrane [1; 16].
anidulafungin and Micafungin are freely soluble in
water.  caspofungin  is  freely  soluble  in  water  and
methanol,  and  slightly  soluble  in  ethanol.  because 
of their inconsistent oral absorption, echinocandins
are available only for intravenous use. Micafungin is
prepared  as  a  powder  ready  for  reconstitution  and 
excipients  include  lactose,  citric  acid,  and  sodium 
hydroxide.  Reconstituted  solution  is  stable  at  room
temperatures for 48h (if protected from light). caspo-
fungin is provided as a lyophylised powder and excipi-
ents include sucrose, mannitol, acetic acid, and sodi-
um hydroxide. It can be stored (refrigerated) for up 
to  24h  after  reconstitution.  anidulafungin  is  also 
provided as a lyophylised powder for reconstitution.
the vial must be reconstituted with water for injec-
tions  and  subsequently  diluted  with  (0.9%)  sodium
chloride  for  infusion  or  (5%)  glucose  for  infusion.
chemical and physical in-use stability of the infusion
solution has been demonstrated for 24 hours at 5ﾺc
[12-14; 16]. 
MEcHanIsM of actIon
the target of echinocandins, b-1,3-d-glucan syn-
thase is an integral part of the fungal cell wall and
consists of two subunits, fksp and Rho1p. fksp is the
active  side  of  the  enzyme  and  is  encoded  by  three
genes (fKs1, fKs2 and fKs3). fKs1 transcription is
cell-cycle regulated, and linked to cell-wall remodeling.
fKs2 transcription is calcineurin-dependent [2]. cal-
cineurin-inhibitors such as tacrolimus seem to enhance
the echinocandin activity in vitro, similar as it is sup-
posed for synergistic activity of fluconazole with cy-
closporine a [17; 18]. Rho1p is thought to be a key
switch, driving or arresting the synthesis of b-1,3-glu-
can. b-1,3-d-glucan provides along with chitin the in-
tegrity and shape of the cell wall. blocking of its syn-
thesis results in osmotic lysis of the cell, thus leading
to  fungicidal  activity  of  the  echinocandins  against
Candida species  [16].  the  cell-wall  is  not  a  part  of
mammalian cells, and therefore an excellent target for
antifungal agents.
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Fig. 1. chemical structure of echinocandins.
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Echinocandins are know to be active against Candida
and  Aspergillus species  but  are  also  active  against
Pneumocystis jirovecii. they are not active at clinically
relevant concentrations against Zygomycetes, Crypto-
coccus neoformans, or Fusarium species [2]. consider-
ing the family of yeast which is the main subject of
this review, echinocandins display in vitro and in vivo
fungicidal  activity  against  most  Candida species,  in-
cluding Candida  albicans, Candida  glabrata, Candida
tropicalis,  Candida  dubliniensis,  and  Candida  krusei.
they are less active against Candida parapsilosis and
Candida guilliermondii, with higher minimum inhibito-
ry concentrations for these species [19]. the MIc50 of
caspofungin  and  anidulafungin  against  C.  albicans
ranges from <0.01ﾵg/ml to >8ﾵg/ml, and that of
micafungin  from  ≤0.01ﾵg/ml  to  0.5ﾵg/ml.  the
MIc90 against C. albicans ranges from 0.01 ﾵg/ml to
0.5  ﾵg/ml  for  anidulafungin;  0.01  ﾵg/ml  to  0.25
ﾵg/ml  for  micafungin,  and  from  0.12  ﾵg/ml  to  1
ﾵg/ml for caspofungin, respectively [19-22]. accord-
ingly, the clsI subcommittee has decided to recom-
mend a "susceptible only" breakpoint MIc of < or =
2 ﾵg/ml due to the lack of echinocandin resistance in
the population of Candida isolates [20]. 
the activity is comparable between the three agents
and all of them present much lower MIcs than ampho-
tericin b and fluconazole against common Candida spp.
[19]. the exception are Candida parapsilosis and Candi-
da guilliermondii for which minimal inhibitory concen-
trations are typically higher and range from 0.5 ﾵg/ml
to  4.0  ﾵg/ml.  breakthrough  bloodstream  infections
(bsI) with Candida  parapsilosis and Candida  guillier-
mondii as well as progressive Candida oesophagitis with
Candida albicans have been observed in patients receiv-
ing caspofungin [23-28]. some data indicate that anidu-
lafungin could have lower MIcs against C. parapsilosis
and  C.  glabrata strains  that  demonstrate  enhanced
MIcs  to  caspofungin  and  micafungin  [23].  whether
this is clinically meaningful needs to be established.
REsIstancE
the incidence of resistance to echinocandins is rare, but
some case reports have illustrated the potential for re-
sistance development [24-27; 29]. Mutations of the fKs
gene have been indentified to cover echinocandins re-
sistance in most cases. specifically fKs1 mutations were
found to be associated with a profound decrease in sus-
ceptibility to echinocandins [16; 24; 30; 31]. It is sup-
posed that these mutations result in cross-resistance to
all agents in the class. the second distinct mechanism
potentially conferring resistance to echinocandins is the
presence of a drug efflux pumps in the fungal cell wall.
the cdr2p gene (also known to contribute to flucona-
zole resistance in C. albicans) was associated with an in-
crease in MIcs of caspofungin. the same phenome-
non, but to a lesser extent, was seen for cdr1p [32].
PHaRMacodynaMIcs
all three echinocandins exhibit concentration-depen-
dent killing against most Candida spp. over a broad
concentration range. the killing efficacy is correlated
with plasma peak (cmax)/MIc ratio or area under the
concentration-time  curve  (auc)/MIc  ratio  [11;  33;
34]. Interestingly, echinocandin activity can be still ob-
served in a drug free environment following drug ex-
posure. It is known as the post – antifungal effect and
is also concentration dependent, with higher concen-
trations resulting in longer post-antifungal effects [35;
36]. according to that phenomenon, extended dosing
intervals might be an option as shown in an animal
model of mice treated with micafungin for disseminat-
ed candidosis [37-39]. In children, a pharmacokinetic
study found that alternate-day dosing of micafungin
given  as  antifungal  prophylaxis  plasma  levels  were
found to remain above the MIcﾴs of susceptible fun-
gal pathogens [40]. However, further studies are need-
ed to support this procedure in clinical practice. an-
other interesting phenomenom is the "eagle effect". In
vitro, a paradoxical increase in fungal growth (“para-
doxical growth”, “eagle effect”) could be observed if
echinocandin concentration was increased above the
organism’s MIc [41-43]. However, this effect varies re-
markably  between  the  three  echinocandins  [44].  In
four  different  Candida species  alterations  were  ob-
served in cell wall components and ultrastructure asso-
ciated  with  paradoxical  growth  [42].  In  paradoxical
growth cells, b-1,3-glucan content decreased from 2.7-
to 7.8-fold, whereas chitin content increased from 4.0-
to 6.6-fold. High concentrations of the echinocandin
could depress resistance mechanisms but the clinical
relevance of this phenomenon is unknown.
actIvIty agaInst bIofIlMs
candidemia  is  often  associated  with  intravascular
catheters,  which  can  be  complicated  by  building  of
biofilms that consist of sessile cells. contrary to flu-
conazole, all three echinocandins were shown to be ac-
tive  against  biofilms.  caspofungin,  micafungin  and
anidulafungin exhibit activity against sessile cells of C.
albicans,  C.  dubliniensis,  C.  glabrata and  C.  krusei
which can be of clinical relevance [45-49].
PHaRMacoKInEtIcs
In general, because of their large molecular weight,
echinocandins  are  poorly  bioavailable  for  oral  use, 
and therefore they are approved only for intravenous
administration. However, one echinocandin (enfuma-
fungin)  potentially  suitable  for  oral  use  is  currently
under investigation [50]. all echinocandins distribute
well into tissues, but none of them penetrate suffi-
ciently  the  cns  or  the  eye,  therefore  they  are  not 
recommended  as  drug  of  choice  for  treatment  of 
patients  with  fungal  meningitis  or  endophthalmitis 
[8; 51]. animal models suggest the potential useful-
ness  of  the  echinocandins  in  Candida meningoen-
cephalitis  although  higher  doses  might  be  required 
(as  studied  for  micafungin)  but  this  needs  further 
clinical investigation [34; 52]. the echinocandins are
not dialyzable, and there is no need for supplemental
doses  after  haemodialysis.  dose  adjustment  is  also 
not required in patients with renal impairment. Phar-
macokinetic data in the public domain to support this
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gin [53].
a  high  protein  binding  is  typical  for  all  three
echinocandins (>95%; see table 1). none of them is a
major p-glycoprotein substrate and none is significant-
ly metabolized by the cytochrome P450 [16]. of note,
when caspofungin is co-administered with inducers of
metabolic enzymes, an increase in the daily dose to 70
mg, following the 70 mg loading dose, should be con-
sidered in adult patients. Major differences are related
to  the  route  of  metabolism  and  half-  life  [54-57].
therapeutic drug monitoring is not generally indicat-
ed. However, plasma levels of caspofungin may be in-
creased in severely ill patients treated in the surgical
Icu, in particular when albumin concentration in plas-
ma is low [58; 59]. for micafungin, a study on popula-
tion  pharmacokinetics  found  that  patients  weighing
66.3 kg or more need a higher  daily dose of micafun-
gin (150mg) to achieve an auc0-24 comparable to pa-
tients <66.3kg receiving 100mg/day [57].
caspofungin  is  characterized  by  a  moderate  non-
linear  pharmacokinetics  with  increased  accumulation
as the dose is increased, and a dose dependency in the
time to reach steady state upon multiple-dose adminis-
tration. In contrast to a short ʱ-phase and a predomi-
nat b-phase that exhibits log linearity, a long ʳ-phase
appears to be nonlinear and responsible for the accu-
mulation  of  caspofungin  over  time.  the  dosage  of
caspofungin is a 70-mg loading dose followed by 50
mg once/day, resulting in a through concentration of
at least 1 ﾵg/ml. Higher dosages of caspofungin (up
to 150mg/d) have been studied in clinical trials sug-
gesting a higher efficacy in subgroups of patients and
a  dose-related  response  [60;  61].  the  metabolism  is
slow,  it  undergoes  spontaneous  disintegration  to  an
open-ring  compound  followed  by  peptide  hydrolysis
and n-acytylation into two inactive metabolites in the
liver [62; 63]. the half-life of caspofungin is 9-11h (s.
table 1). an additional gamma-phase also occurs with
a half-life of 45 hours. the elimination of caspofun-
gin  from  plasma  is  slow  with  a  clearance  of  10-12
ml/minute. approximately 75 % of a radioactive dose
was recovered during 27 days: 41 % in urine and 34 %
in faeces. a small amount of caspofungin is excreted
unchanged  in  urine  (approximately  1.4  %  of  dose)
[13].
Micafungin is characterized by linear pharmacoki-
netics over the daily dose range of 12.5 mg to 200 mg
and 3 mg/kg to 8 mg/kg. there is no evidence of sys-
temic accumulation with repeated administration and
steady-state is reached within 4 to 5 days. It is metabo-
lized  into  three  metabolites.  the  first  metabolite  is
formed by arylsulfatase and further degraded by cate-
chol-O-methyl-transferase  to  the  second  metabolite.
the third metabolite is the result of the side chain hy-
drolysis by cyP3a, but this pathway does not play a
significant role in the drug metabolism. the degrada-
tion  products  are  excreted  slowly  over  many  days,
mainly in the bile. following intravenous administra-
tion concentrations of micafungin show a biexponen-
tial decline. the drug is rapidly distributed into tissues.
In systemic circulation, micafungin is highly bound to
plasma protein (> 99%), primarily to albumin. binding
to albumin is independent of micafungin concentra-
tion  (10-100  ʼg/ml).  the  volume  of  distribution  at
steady state (vss) was approximately 18-19 litres. the
mean terminal half-life is approximately 10-17 hours
and stays consistent across doses up to 8 mg/kg and
after single and repeated administration. total clear-
ance was 0.15-0.3 ml/min/kg in healthy subjects and
adult patients and is independent of dose after single
and repeated administration. following a single intra-
venous  dose  of  14c-micafungin  (25  mg)  to  healthy
volunteers, 11.6% of the radioactivity was recovered
in the urine and 71.0% in the faeces over 28 days. no
loading dose is required for micafungin [14]. Recom-
mended standard dosages vary according to the indica-
tion and body weight. for treatment of invasive candi-
dosis  in  adults  the  daily  dose  is  100mg/d  (children
2mg/kg/d if body weight is ≤40kg), for treatment of
oesophageal  candidosis  the  daily  dose  is  150mg/d
(children 3mg/kg/d if body weight is ≤40kg), and for
prophylaxis of Candida infections in stem cell recipi-
ents the daily dose is 50mg/d (children 1mg/kg/d if
body weight is ≤40kg) [64-66].
anidulafungin  displays  linear  pharmacokinetics
across a wide range of once daily doses (15-130 mg).
a low intersubject variability in systemic exposure was
observed. the steady state was achieved on the first
day  after  a  loading  dose.  It  undergoes  slow  sponta-
neous  biotransformation  into  an  inactive  open-ring
peptide, and is excreted in the bile [12]. no liver me-
tabolism  has  been  observed.  anidulafungin  is  not  a
clinically  relevant  substrate,  inducer,  or  inhibitor  of
cytochrome P450 isoenzymes.  the pharmacokinetics
of anidulafungin are characterised by a rapid distribu-
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Table 1. Pharmacokinetics of echinocandins for the treatment of candida infections
Parameter anidulafungin caspofungin micafungin
Mode of administration Iv Iv Iv
dose linearity  ++ +
oral availability [%] n/a n/a n/a
Plasma protein binding [%] 99 97 99
volume of distribution [l] 30-50 n/a 18
Elimination half-life [h] 24 9-11 10-17
Route of elimination d,  d / M M
f u > f f > u
E = excretion unchanged; M = drug is metabolised; d = drug is degraded; u = urine; f = faeces
4) Ruhnke_Umbruchvorlage  23.03.11  12:33  Seite 162tion half-life (0.5-1 hour) and a volume of distribu-
tion, 30-50 l, which is similar to total body fluid vol-
ume.  anidulafungin  is  extensively  bound  (>99%)  to
human plasma proteins. no specific tissue distribution
studies of anidulafungin have been done in humans.
therefore, no information is available about the pene-
tration of anidulafungin into the cerebrospinal fluid
(csf) and/or across the blood-brain barrier. the tis-
sue concentrations can reach ten times that of plasma
as indicated by animal studies [67]. the clearance of
anidulafungin is about 1 l/h. anidulafungin has a pre-
dominant elimination half-life of 24 hours that charac-
terises the majority of the plasma concentration-time
profile,  and  a  terminal  half-life  of  40-50  hours  that
characterises  the  terminal  elimination  phase  of  the
profile. the steady state cmax and trough concentra-
tions (cmin) after standard dosing (loading 200mg fol-
lowed by 100mg) on day 1 is about 7 and 3 mg/l, re-
spectively. approximately 30% of the administered ra-
dioactive dose was eliminated in the faeces over 9 days,
of which less than 10% was intact drug. less than 1%
of the administered radioactive dose was excreted in
the urine, indicating negligible renal clearance. weight
was identified as a source of variability in clearance in
the  population  pharmacokinetic  analysis,  but  so  far
weight has little clinical relevance on the pharmacoki-
netics of anidulafungin, yet. a dose finding study has
been  performed  ranging  from  50  to  100mg/d  (re-
ceived a loading dose of twice the daily maintenance
dose given as a single infusion on day 1) for the indica-
tion  candidaemia  which  found  that  higher  dosages
(75mg and 100mg/d) are more effective [68]. a large
double-blind trial in 601 patients with endoscopically
and microbiologically documented esophageal candi-
dosis comparing oral fluconazole (200 mg on day 1,
followed by 100 mg per day) with intravenous anidula-
fungin (100 mg on day 1, followed by 50 mg per day)
for  7  days  beyond  resolution  of  symptoms  (range,
14–21 days) found anidulafungin equally effective [69].
the currently licensed standard dosage of anidulafun-
gin is a 200mg loading dose followed by 100mg once
daily. 
sPEcIal PoPulatIons
PatIEnts wItH HEPatIc IMPaIRMEnt
dose adjustment is also not required in patients with
mild  and  moderate  hepatic  impairment  for  all  three
agents.  the  auc  may  be  increased  up  to  75%  for
caspofungin and a dose reduction to 35mg/d mainte-
nance therapy is recommended. However, caspofungin
and micafungin were not studied in adults with severe
hepatic  impairment  as  well  as  in  children  (all
echinocandins) with any degree of hepatic impairment
and should not be given in these situations [12-14].
only anidulafungin has been studied in patients with
severe hepatic impairment and may be given in this
condition  [53].  anidulafungin  is  not  metabolized  by
the liver and no enhanced serum levels of liver en-
zymes have been found with any level of hepatic im-
pairment. Patients who develop abnormal liver func-
tion tests during treatment with micafungin should be
evaluated for the risk/benefit ratio. the development
of foci of altered hepatocytes (faH) and hepatocellu-
lar tumors after a treatment period of three months or
longer were observed in rats with micafungin. because
development of hepatocellular tumors in humans can-
not be excluded, a warning was added to the package
insert. no dose adjustment is needed for caspofungin
in patients with mild hepatic disease, but in case of
moderate  disease,  the  70mg  loading  dose  should  be
followed by 35mg once daily [12-14].
PEdIatRIc PatIEnts
Micafungin is approved for use in neonates and chil-
dren.  auc  values  were  dose  proportional  over  the
dose range of 0.5-4 mg/kg. clearance was influenced
by age, with mean values of clearance in younger chil-
dren (2-11 years) being approximately 1.3 -fold greater
than those in older children (12-17 years). older chil-
dren had mean clearance values similar to those deter-
mined in adult patients. Mean clearance in premature
infants is approximately 5-fold greater than in adults
[56; 70]. 
caspofungin  is  approved  for  use  in  children  (12
months  to  17  years).  In  children  receiving  1
mg/kg/day caspofungin (maximum, 50 mg/day), the
area  under  the  concentration-time  curve  over  24  h
(auc0–24) was significantly smaller (46% after multi-
ple  doses)  than  that  observed  in  adults  receiving
50mg/day.  In  children  and  adolescents  receiving  50
mg/m2/day  (maximum,  70  mg/day),  the  auc0–24
following multiple doses was similar to that for the ex-
posure  in  adults  receiving  50  mg/day.  accordingly,
caspofungin  administration  at  50  mg/m2/day  pro-
vides a comparable exposure in children (12 months
to 17 years) to that of adult patients treated with 50
mg/day [63].
anidulafungin is currently not approved for use in
children. Pediatric patients with neutropenia (2 – 17
years  of  age)  receiving  0.75  mg/kg/day  or  1.5
mg/kg/day  had  anidulafungin  concentration  profiles
similar to those of adult patients receiving 50 or 100
mg/day, respectively [71].
gERIatRIc PoPulatIon, PREgnant woMEn and
nuRsIng MotHERs
no dose adjustment is required for geriatric popula-
tion.  all  echinocandins  have  embryo  toxic  potential
and all three of them have been found in the breast
milk of rats. therefore, they should only be used dur-
ing pregnancy or in nursing women if benefits over-
weigh the risks [12-14]. 
dRug IntERactIons
Echinocandins are poor substrates for the cytochrome
P450  enzymes  (caspofungin  is  the  most  dependent
echinocandin on the cyP450 system and anidulafun-
gin shows the least interaction potential). they also do
not  influence  the  P-glycoprotein  family.  therefore,
there are very few known drug-drug interactions with
these  drugs.  Rifampin,  nevirapine,  efavirenz,  carba-
mazepine, phenytoin, and dexamethasone can induce
the clearance of caspofungin. Increasing the dose of
caspofungin to 70 mg daily should be considered if
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transient elevations of liver function tests have been
observed  in  patients  receiving  caspofungin  and  cy-
closporine (csa; and/or tacrolimus) in a phase I trial
[72]. although csa is a potent inhibitor of cyP3a4
and P-glycoprotein, these pathways are not involved in
the metabolism of caspofungin. However, in two co-
horts of stem cell and organ (liver) transplant patients
receiving  concomitantly  caspofungin  with  cyclo  -
sporine a or tacrolimus, no or mild liver enzyme ele-
vation  was  observed  [73;  74].  caspofungin  interacts
with tacrolimus and reduces its auc by 20%. Moni-
toring  of  drug  concentrations  of  tacrolimus  is  re-
quired in patients who receive both drugs. Interesting-
ly,  both  csa  and  tacrolimus  exhibit  a  clear  in  vitro
positive  interaction  with  caspofungin  against  as-
pergillus fumigatus in vitro. Microscopic morphologi-
cal analyses indicate that the calcineurin inhibitors de-
lay filamentation, and in combination with caspofun-
gin there is a positive interaction. these findings even
suggest a potential role for combination therapy with
calcineurin pathway inhibitors [75]. Micafungin has a
potential to increase concentrations of sirolimus, itra-
conazole  and  nifedipine.  dose  reduction  of  these
drugs may be required. coadministration with tacro  -
limus, cyclosporine, fluconazole, prednisolone, riton-
avir and rifampin do not alter the pharmacokinetic of
any of the drugs [14]. 
no dosage adjustments are necessary for anidula-
fungin if coadministered with any other drug [12].
safEty and advERsE dRug REactIons
Echinocandins  are  contraindicated  in  patients  with
known  hypersensitivity  to  the  agents  or  any  of  its
components.  as  mentioned  above,  micafungin  in-
cludes a warning of possible development of liver tu-
mors. In general, the echinocandins are well tolerated
and similar in types of adverse effects. they have a fa-
vorable safety profile compared to other antifungals.
Infusion related reactions may occur after use of all
three echinocandins (<5%), but they respond well to
antihistamines  and  the  drug  needs  not  to  be  with-
drawn.  thrombophlebitis  may  occur  as  well  (<3%;
primarily seen in HIv infected patients with peripheral
lines) but infusion-related reactions were less frequent-
ly  observed  as  compared  to  liposomal  amphotericin
when  used  as  empiric  antifungal  therapy  in  patients
with  persistent  fever  and  granulocytopenia  [76].
caspofungin has a somewhat higher frequency of liv-
er-related laboratory abnormalities (1-15%) compared
to the other two drugs [1]. nausea, vomiting, diarrhea
and other mild gastrointestinal symptoms are possible,
but rare.
PHaRMaco-EconoMIc EvaluatIons
Pharmaco-economic analysis revealed that echinocan-
dins (caspofungin, micafungin) may be more cost-ef-
fective than liposomal amphotericin b in the treatment
of suspected fungal infections, especially for azole-re-
sistant cases and in patients with renal impairment [77;
78]. In fluconazole-susceptible invasive Candida infec-
tions (C. albicans), anidulafungin was found to be su-
perior than the azole antifungal in a randomized trial
[79].  whether  anidulafungin  is  cost-effective  more
than  fluconazole  needs  to  be  further  analyzed.  In  a
model with inputs from the literature in a hypothetical
1000-patient cohort with suspected Icu-acquired in-
vasive candidosis (Icu-ac) treated empirically with ei-
ther  micafungin  or  fluconazole  or  no  treatment  ac-
companied by a watchful waiting strategy, treatment of
suspected Icu-ac (for fluconazole-resistant Candida
spp.) with the echinocandin at a dose of 100 mg daily
was a cost-effective alternative compared with 400 mg
daily flu or observation alone [80]. 
Most of these reports were supported by the corre-
sponding  manufacturer  of  the  antifungal  drug  and
confirmation of these findings in independent studies
is awaited.
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